Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 101Endometrial Neoplasms 74Uterine Cervical Neoplasms 63Carcinoma, Non-Small-Cell Lung 56Colorectal Neoplasms 50Melanoma 49Triple Negative Breast Neoplasms 42Carcinoma, Renal Cell 41Stomach Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Fallopian Tube Neoplasms 33Breast Neoplasms 33Pancreatic Neoplasms 27Neoplasms 25Esophageal Neoplasms 24Carcinoma, Transitional Cell 24Neoplasm Metastasis 23Carcinoma, Hepatocellular 20Lung Neoplasms 19Carcinoma, Ovarian Epithelial 19Small Cell Lung Carcinoma 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 17Prostatic Neoplasms 14Cholangiocarcinoma 13Carcinoma, Merkel Cell 11Kidney Neoplasms 10Mesothelioma 9Uterine Neoplasms 8

Interventions

Paclitaxel 4liposomal doxorubicin 3Carboplatin 3pembrolizumab 2Bevacizumab 21-dodecylpyridoxal 2poly(I).poly(c12,U) 1mirabegron 1disitamab vedotin 1apatinib 1anlotinib 1Tocotrienols 1Platinum Compounds 1Lenalidomide 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1EP-100 membrane-disrupting peptide 1Cisplatin 1AC 7700 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Cancer Recurrent × pembrolizumab × Gynecologic × Clear all
NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
460 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

University of Pittsburgh

Phase 1/2 Active not recruiting
24 enrolled 59 charts
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡